Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2024-07-11 Share Issue/Capital Cha…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated July 11, 2024, announcing three key items: the cash position as of June 30, 2024, an update on the Batten-1 program, and the implementation of a new equity line (a financing arrangement involving Warrants and Bonds). The core of the announcement details the terms of this new financing mechanism, including dilution estimates and share capital tables. This content directly relates to fundraising, capital structure changes, and financing activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it is a detailed announcement about securing new capital, CAP is the most appropriate classification.
2024-07-11 English
Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avancement de Batten-1
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated July 11, 2024, announcing two main items: the company's cash position as of June 30, 2024, and the establishment of a new equity financing line (a line of credit convertible into shares) with an investor named IRIS, totaling up to €2.5 million. The text details the terms of this financing, including the issuance of warrants ('Bons') convertible into redeemable shares ('Obligations'), and discusses the potential dilution. This content directly relates to fundraising, capital structure changes, and financing activities. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER) which focuses only on key results, or a general regulatory filing (RNS), as it is a specific corporate action announcement.
2024-07-11 French
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE '2024 RESEARCH PACT' PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Regulatory Filings Classification · 1% confidence The document is a press release dated July 3rd, 2024, announcing that Theranexus, along with partners, won a regional research project funding (€320,000) for developing neuroimaging tools related to drug candidates. This announcement details a specific operational/research development and funding achievement, rather than a mandatory periodic financial filing (like 10-K or IR), a management change (MANG), or a formal dividend/share transaction (DIV/POS). It is a general corporate announcement regarding R&D progress and funding. Since it is not a standard regulatory filing like 10-K, IR, or ER, and it doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate general category for a significant, non-standard corporate update that isn't a formal report announcement is 'Regulatory Filings' (RNS) as a catch-all for important press releases that don't fit elsewhere, although 'Capital/Financing Update' (CAP) could be considered due to the funding aspect. However, the core focus is the research pact win, not a capital raise or debt issuance. Given the options, RNS serves as the best fit for a general, material press release that isn't a core financial report or specific corporate action.
2024-07-03 English
THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET ' PACTE DE RECHERCHE 2024 ' DE LA REGION AUVERGNE-RHÔNE-ALPES
Regulatory Filings Classification · 1% confidence The document is a press release dated July 3, 2024, announcing that Theranexus, along with research centers, has won a research grant ('Pacte de recherche 2024') from the Auvergne-Rhône-Alpes region. It details the project (IMASO), the funding amount (€320,000), and quotes the CEO and a Professor regarding the continuation of their joint research laboratory (NI2D) focused on neuroimaging for drug discovery. This type of announcement, detailing a specific corporate/research development, funding award, or partnership, does not fit the definitions for 10-K, ER, IR, or AGM-R. It is a general corporate announcement. Since it is not a management change (MANG), director dealing (DIRS), dividend notice (DIV), or capital change (CAP), the most appropriate general category for a significant, non-standard regulatory or corporate update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a general announcement mechanism for material, non-standard news.
2024-07-03 French
Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Regulatory Filings Classification · 1% confidence The document is a press release dated June 6, 2024, announcing positive 18-month results for the drug Batten-1 in a Phase I/II trial, citing biomarker data (neurofilaments) and quotes from the CEO and principal investigator. This content structure—announcing clinical trial updates, efficacy data, and future plans (Phase III trial)—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses specifically on clinical trial results and not comprehensive quarterly financial performance (which would suggest an IR or 10-K), and it is a formal announcement of results rather than just a link to a report (ruling out RPA/RNS based on length and content), the most appropriate classification is Earnings Release (ER), as clinical trial updates often accompany or substitute for detailed earnings discussions in biotech/pharma sectors, or it could be classified as a Regulatory Filing (RNS) if it were less specific. Given the detailed nature of the results announcement, ER is a strong fit, though it also contains elements of Investor Presentation material. However, ER is used for initial announcements of periodical financial results (which clinical updates often accompany). If this were a standalone announcement of a major clinical milestone without any financial context, RNS might be considered, but the context of 'positive results' strongly aligns with the timing of earnings announcements. I will classify it as ER as it is a major periodic update on company progress, often released around earnings periods.
2024-06-06 English
Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Earnings Release Classification · 1% confidence The document is a press release dated June 6, 2024, announcing positive 18-month results from the Batten-1 Phase 1/2 study, specifically mentioning a decrease in NfL biomarkers. It includes quotes from the CEO and principal investigator, details about the drug (Batten-1/miglustat), the study design, and future plans (Phase 3 pivotale). This format—a formal announcement of key periodic results (clinical trial data update) intended for immediate public dissemination—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical milestones. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a presentation (IP), the most fitting category for a primary announcement of financial/clinical performance highlights is 'Earnings Release' (ER), as clinical trial updates often serve the same function as earnings announcements for biotech firms, detailing performance and outlook. It is a direct announcement of results, not an announcement *about* a report (RPA). FY 2024
2024-06-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.